Trial Profile
A Randomized, Stratified, Open-label, No-treatment-controlled, Parallel Group, Multicenter Phase 1 Trial to Evaluate the Effect of Denosumab on Cellular Proliferation in the Human Breast
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Bone cancer; Male osteoporosis; Osteoporosis; Postmenopausal osteoporosis
- Focus Biomarker; Pharmacodynamics
- Sponsors Amgen
- 09 Mar 2015 Status changed from active, no longer recruiting to completed reported by ClinicalTrials.gov.
- 23 Jan 2015 Planned End Date changed from 1 Dec 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov
- 14 Oct 2014 Planned End Date changed from 1 Oct 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov record